Q-omics provides the consensus-scored ADAM30 profile across patient tissues and cancer cell-line models. ADAM30 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADAM30 is differentially expressed in 1, with the highest sampling consensus in UCEC. Additionally, ADAM30 protein abundance shows 8,758 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, UCEC, and GBM as cancer lineages where ADAM30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM30 survival associations across molecular data types. ADAM30 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM30 RNA expression–survival associations across cancer types. High ADAM30 expression shows unfavorable associations in UVM, ACC, THCA, KICH and READ, but favorable associations in KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ADAM30 RNA expression.
This table summarizes ADAM30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAM30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM30 shows higher tumor expression in UCEC. The UCEC box plot shows higher ADAM30 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .037).
This table shows molecular features associated with ADAM30 in patient tissues and cancer cell lines. In patient samples, ADAM30 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAM30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_NSCLC_LUAD.
